Top

Published in:

01-07-2015 | Original Paper

Regulation of BAX/BCL2 gene expression in breast cancer cells by docetaxel-loaded human serum albumin nanoparticles

Authors: Marzieh Kordezangeneh, Shiva Irani, Reza Mirfakhraie, Mehdi Esfandyari-Manesh, Fatemeh Atyabi, Rassoul Dinarvand

Published in: Medical Oncology | Issue 7/2015

Abstract

Today, using nanoparticle-based drug delivery systems has expanded to avoid anticancer side effects. Taxanes are important chemotherapeutic agents in the treatment of metastatic breast cancer. In this study, docetaxel (DTX)-loaded human serum albumin (HSA) nanoparticles (NPs) were prepared and characterized. Drug toxicity of the nanoparticles was measured by MTT assay with different drug concentrations (0.01, 0.1, 0.5, 1 and 5 μM) at different incubation times (24, 48 and 72 h). Expression of BAX/BCL2 mRNA levels was determined by real-time PCR. The size of NPs prepared and used in our study was about 147 nm with surface charge of −29.6 mV. Results obtained from MTT assay showed that 0.5 μM of free drug had 50 % toxicity on MCF-7 cells after 48-h incubation. Real-time PCR results showed an increase in expression of BAX and no change for BCL2. In conclusion, a significant overexpression of BAX gene and changes in BAX/BCL2 ratio were observed for DTX-loaded HSA nanoparticles compared with free DTX and may provide a potential therapy to inhibit anticancer drug resistance.

Taghavi A, Fazeli Z, Vahedi M, Baghestani A, Pourheseingholi A, Barzegar F, Pourheseingholi M. Increased trend of breast cancer mortality in iran. APJCP. 2012;13(1):367–70.PubMed

Fridman A, Chirokov A, Gutsol A. Non-thermal atmospheric pressure discharges. Phys. 2005;38:R1–24.

Zumoff B. Adjuvant treatment in breast cancer. Lancet. 1992;339:423–4.PubMedCrossRef

Smith G, Henderson IC. New treatments for breast cancer. Semin Oncol. 1996;23:506–28.PubMed

Haldar S, Basu A, Croce CM. Bcl2 is the guardian of microtubule integrity. Cancer Res. 1997;57:229–33.PubMed

Gumerlock P, Mack P, Gustafsson M, Togonon M, Gandara D. p27 induction as a potential p53-independent mechanism of apoptotic response to docetaxel in non-small cell lung (NSCL) and prostate carcinomas (CaP). Clin Cancer Res. 1999;5:s3859.

Herbst RS, Khuri FR. Mode of action of docetaxel a basis for combination with novel anticancer agents. Cancer Treat Rev. 2003;29:407–15.PubMedCrossRef

Bissery MC, Nohynek G, Sanderink GJ, Lavelle F. Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I: preclinical experience. Anti-Cancer Drugs. 1995;6:339–55.PubMedCrossRef

Kwon GS, Okano T. Polymeric micelles as new drug carriers. Adv Drug Deliv Rev. 1996;21:107–16.CrossRef

10.

Panday VRN, Huizing MT, Huinink WWTB, Vermorken JB, Beijnen JH. Hypersensitivity reactions to the taxanes paclitaxel and docetaxel. Clin Drug Invest. 1997;14:418–27.CrossRef

11.

Riley T, Stolnik S, Heald CR, Xiong CD, Garnett MC, Illum L, Davis SS. Physicochemical evaluation of nanoparticles assembled from poly (lactic acid)-poly (ethylene glycol) (PLA-PEG) block copolymers as drug delivery vehicles. Langmuir. 2001;17:3168–74.CrossRef

12.

Savic R, Luo L, Eisenberg A, Maysinger D. Micellar nanocontainers distribute to defined cytoplasmic organelles. Science. 2003;300:615–8.PubMedCrossRef

13.

Deim K. Synopsis of plasma proteins scientific tables, vol. 6. DocumentaGeigy: Geigy Pharmaceuticals, Ardsley; 1962.

14.

Sebak S, Mirzaei M, Malhorta M, Kulamarva A, Prakash S. Human serum albumin nanoparticles as an efficient noscapine drug delivery system for potential use in breast cancer: preparation and in vitro analysis. Int J Nanomed. 2010;5:525–32.

15.

Kratz F, Muller DR, Hofmann I, Drevs J, Unger C. A novel macromolecular prodrug concept exploiting endogenous serum albumin as a drug carrier for cancer chemotherapy. J Med Chem. 2000;43:1253–6.PubMedCrossRef

16.

Giannoukakis N. Current opinion in investigational drugs (London, England: 2000). CJC-1131. 2003;4:1245–9.

17.

Chipuk JE, Fisher JC, Dillon CP, Kriwacki RW, Kuwana T, Green DR. Mechanism of apoptosis induction by inhibition of the anti-apoptotic BCL-2 proteins. Proc Natl Acad Sci. 2008;105:20327–32.PubMedCentralPubMedCrossRef

18.

Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol. 2008;9:47–59.PubMedCrossRef

19.

Walensky LD, Gavathiotis E. BAX unleashed: the biochemical transformation of an inactive cytosolic monomer into a toxic mitochondrial pore. Trends Biochem Sci. 2011;36:642–52.PubMedCentralPubMedCrossRef

20.

Chipuk JE, Moldoveanu T, Llambi F, Parsons MJ, Green DR. The BCL-2 family reunion. Mol Cell. 2010;37:299–310.PubMedCentralPubMedCrossRef

21.

Bai L, Wang S. Targeting apoptosis pathways for new cancer therapeutics. Annu Rev Med. 2014;65:139–55.PubMedCrossRef

22.

Green DR, Beere H, Hickman JA, Dive C. Apoptosis and cancer chemotherapy: mechanisms of apoptosis. New Jersey: Humana Press; 1999. p. 157–74.CrossRef

23.

Siervo-Sassi RR, Marrangoni A, Feng X, Naoumova N, Winans M, Edwards RP, Lokshin A. Physiological and molecular effects of Apo2L/TRAIL and cisplatin in ovarian carcinoma cell lines. Cancer Lett. 2003;190:61–72.PubMedCrossRef

24.

Thomadaki H, Scorilas A. Breast cancer cells response to the antineoplastic agentscisplatin, carboplatin, and doxorubicin at the mRNA expression levels of distinct apoptosis-related genes, including the new member, BCL2L12. Ann N Y Acad Sci. 2007;1095:35–44.PubMedCrossRef

25.

Elzoghby AO, Samy WM, Elgindy NA. Albumin-based nanoparticles as potential controlled release drug delivery systems. J Control Release. 2012;157:168–82.PubMedCrossRef

26.

Chen W, Gu B, Wang H, Pan J, Lu W, Hou H. Development and evaluation of novel itraconazole-loaded intravenous nanoparticles. Int J Pharm. 2008;362:133–40.PubMedCrossRef

27.

Stehle G, Sinn H, Wunder A, Schrenk HH, Stewart JC, Hartung G, Maier-Borst W, Heene DL. Plasma protein (albumin) catabolism by the tumor itself—implications for tumor metabolism and the genesis of cachexia. Crit Rev Oncol Hematol. 1997;26:77–100.PubMedCrossRef

28.

John TA, Vogel S, Tiruppathi C, Malik AB, Minshall RD. Quantitative analysis of albumin uptake and transport in the rat microvessel endothelial monolayer. Am J Physiol Lung Cell Mol Physiol. 2003;284:L187–96.PubMedCrossRef

29.

Desai N, Trieu V, Yao Z, Louie L, Ci S, Yang A, Tao C, De T, Beals B, Dykes D, Noker P, Yao R, Labao E, Hawkins M, Soon-Shiong P. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res. 2006;12:1317–24.PubMedCrossRef

30.

Malam Y, Loizidou M, Seifalian AM. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol Sci. 2009;30:592–9.PubMedCrossRef

31.

Miele E, Spinelli GP, Miele E, Tomao F, Tomao S. Albumin-bound formulation of paclitaxel (Abraxane^® ABI-007) in the treatment of breast cancer. Int J Nanoedicine. 2009;4:99–105.

32.

Chew L, Chuen V. Cutaneous reaction associated with weekly docetaxel administration. J Oncol Pharm Pract. 2009;15:29–34.PubMedCrossRef

33.

Akay BN, Unlu E, Buyukcelik A, Akyol A. Photosensitive rash in associationwithporphyrin biosynthesis possibly induced by docetaxel andtrastuzumab therapy in a patient with metastatic breast carcinoma. Jpn J Clin Oncol. 2010;40:989–91.PubMedCrossRef

34.

Manoochehri S, Darvish B, Kamalinia G, Amini M, Fallah M, Ostad SN, Atyabi F, Dinarvand R. Surface modification of PLGA nanoparticles via human serum albumin conjugation for controlled delivery of docetaxel. Daru J Pharm Sci. 2013;21:58.CrossRef

35.

John TA, Vogel S, Minshall RD, Ridge K, Tiruppathi C, Malik AB. Evidence for the role of alveolar epithelial gp60 in active transalveolar albumin transport in the rat lung. J Physol. 2001;533:547–59.CrossRef

36.

Fritzsche T, Schnolzer M, Fiedler S, Weigand M, Wiessler M, Frei E. Isolation and identification of heterogeneous nuclear ribonucleoproteins (hnRNP) from purified plasma membranes of human tumour cell lines as albumin-binding proteins. Biochem Pharmacol. 2004;67:655–65.PubMedCrossRef

37.

Van Sluis R, Bhujwalla Z, Raghunand N, Ballesteros P, Alvarez J, Cerdan S, Galons J-P, Gillies RJ. In vivo imaging of extracellular pH using 1 H MRSI. Magn Reson Med. 1999;41:743–50.PubMedCrossRef

38.

Cardone RA, Casavola V, Reshkin SJ. The role of disturbed pH dynamics and the Na+ /H+ exchanger in metastasis. Nat Rev Cancer. 2005;5:786–95.PubMedCrossRef

39.

Kanani N, Neumann E, Frei E, Funk D, Becker MD, Schrenk H-H, Müller-Ladner U, Fiehn C. Electroplating-basic principles processes native albumin for targeted drug delivery. Expert Opn Drug Deiv. 2010;7:915–25.CrossRef

40.

Tsujimoto Y. Role of Bcl-2 family proteins in apoptosis: apoptosomes or mitochondria? Genes Cells. 1998;3:697–707.PubMedCrossRef

41.

Borner C. The Bcl-2 protein family: sensors and checkpoints for life-or-death decisions. Mol Immunol. 2003;39:615–47.PubMedCrossRef

42.

Kraus LA, Samuel SK, Schmid SM, Dykes DJ. The mechanism of action of docetaxel (Taxotere^®) in xenograft models is not limited to bcl-2 phosphorylation. Invest New Drugs. 2003;21:259–68.PubMedCrossRef

43.

Nizar MM, Yufang W, Kelly AK, Xu DZ, Peter H. Dcoetaxel-induced apoptosis in melanoma cells is dependent on activation of caspase-2. Mol Cancer Ther. 2007;6:752–61.CrossRef

44.

Lo YL. Phospholipids as multidrug resistance modulators of the transport of epirubicin in human intestinal epithelial Caco-2 cell layers and everted gut sacs of rats. Biochem Pharmacol. 2000;60:1381–90.PubMedCrossRef

45.

Vauthier C, Dubernet C, Chauvierre C, Brigger I, Couvreur P. Drug delivery to resistant tumors: the potential of poly(alkyl cyanoacrylate) nanoparticles. J Control Release. 2003;93:151–60.PubMedCrossRef

46.

Honma K, Iwao KK, Takeshita F, Yamamoto Y, Yoshida T, Nishio K, Nagahara S, Kato K, Ochiya T. RPN2 gene confers docetaxel resistance in breast cancer. Nat Med. 2008;14:939–48.PubMedCrossRef

Title: Regulation of BAX/BCL2 gene expression in breast cancer cells by docetaxel-loaded human serum albumin nanoparticles
Authors: Marzieh Kordezangeneh
Shiva Irani
Reza Mirfakhraie
Mehdi Esfandyari-Manesh
Fatemeh Atyabi
Rassoul Dinarvand
Publication date: 01-07-2015
Publisher: Springer US
Published in: Medical Oncology / Issue 7/2015
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-015-0652-5

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Regulation of BAX/BCL2 gene expression in breast cancer cells by docetaxel-loaded human serum albumin nanoparticles

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2015

Erratum to: Effect of circulating tumor cells combined with negative enrichment and CD45-FISH identification in diagnosis, therapy monitoring and prognosis of primary lung cancer

Influence of an elevated nutrition risk score (NRS) on survival in patients following gastrectomy for gastric cancer

Dysregulated expression of Dicer in invasive ductal breast carcinoma

Lymphatic-targeted therapy following neoadjuvant chemotherapy: a promising strategy for lymph node-positive breast cancer treatment

The crucial role of SRPK1 in TGF-β-induced proliferation and apoptosis in the esophageal squamous cell carcinomas

Short-term cohort study on sensorineural hearing changes in head and neck radiotherapy

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page